Skip to main content
x

AbbVie has Met phase 3, again

The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.

AbbVie already has a cMet-targeting ADC filed with the FDA, and another could follow in the not too distant future. The company is planning to take its next-generation project, telisotuzumab adizutecan, into phase 3 in its lead indication, colorectal cancer, according to a new listing on the clinicaltrials.gov registry.

The trial will test teliso-A monotherapy in patients with refractory colorectal cancer and cMet overexpression – which makes sense given that a cMet-high subgroup performed best in the CRC cohort of a phase 1 basket study.

The control group will receive Lonsurf plus Avastin, a reasonable comparator in late-line disease. The clinicaltrials.gov entry makes no mention of microsatellite status.

Curiously, though, AbbVie has begun phase 3 before readout of a phase 2 CRC trial testing teliso-A alongside fluorouracil, folinic acid and Avastin in previously treated microsatellite-stable patients.

Trials in other uses are also in the works, with an Israeli phase 2 in gastric cancers yet to begin recruiting, and a mid-stage study in NSCLC planned, AbbVie said during its second-quarter earnings call in July.

And more indications could follow, if data from another basket trial look promising.

Teliso-A vs teliso-V

AbbVie recently filed its first-generation cMet ADC, telisotuzumab vedotin, for accelerated approval in EGFR wild type, cMet overexpressing, non-squamous NSCLC. The company estimates that around a quarter of advanced EGFR wild-type NSCLC patients overexpress cMet; however, the most promising response rates with teliso-V have been seen in a smaller subset of patients with high expression levels.

And at this year’s ASCO meeting two deaths were reported as possibly related to teliso-V, caused by interstitial lung disease and respiratory failure.

The FDA will have to weigh up the project’s risks and benefits in a population with no specifically approved therapies. A confirmatory trial, Telimet NSCLC-01, is under way.

Teliso-A, which until recently went under the lab code ABBV-400, could have advantages over teliso-V: the former uses a topoisomerase 1 inhibitor payload, while the latter employs the tubulin inhibitor monomethyl auristatin E.

Certain cMet-targeting projects are already approved, such as Johnson & Johnson's anti-EGFR x cMet MAb Rybrevant, but AbbVie is ahead in the cMet ADC space. Its mid-stage rivals include RemeGen, with RC108, and Regeneron, with the biparatopic project davutamig.

 

Notable trials with telisotuzumab adizutecan

TrialSettingRegimenNote
Ph3 Andrometa-CRCcMet overexpressing refractory metastatic CRCTeliso-A vs Lonsurf + AvastinDue to start Nov 2024; part 1 tests 2 doses of ABBV-400; part 2 tests optimal ABBV-400 dose vs SOC
Ph2 M24-311MSS previously treated metastatic CRCTeliso-A + FFB vs FFB + irinotecanBegan Nov 2023; primary completion Oct 2026
Israeli ph2 Andrometa-GEA-9771st-line gastric cancersTeliso-A + fluorouracil, leucovorin + budiglimumab vs Folfox + budiglimumabNot yet recruiting
Ph1 M21-404Previously treated solid tumours: CRC, GEA, NSCLCTeliso-A +/- AvastinData at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses ≥2.4mg/kg); data at ESMO 2024 in GEA (29% ORR) & NSCLC (44% ORR)
Ph1 M24-427Solid tumours: HCC, PDAC, BTC, ESCC, BC, HNSCCTeliso-A monotherapyPrimary completion Jul 2026

Notes: BC=breast cancer; BTC=biliary tract cancer; CRC=colorectal cancer; FFB=fluorouracil, folinic acid + bevacizumab (Avastin); ESCC=esophageal squamous cell carcinoma; GEA=gastroesophageal adenocarcinoma; HCC=hepatocellular carcinoma; HNSCC=head & neck squamous cell carcinoma; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma. Source: OncologyPipeline.

Tags

Molecular Drug Targets